EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Porton Pharma Solutions and Codexis Launch Global Partnership
PARTNERSHIP
Codexis Inc and Porton Pharma Solutions Ltd announce a strategic collaboration to deploy Codexis worldleading biocatalyst technology within Portons global custom intermediate and active pharmaceutical ingredients API development and manufacturing business The partnership will accelerate the creation and commercialization of new lowcost sustainable manufacturing processes exploiting the benefits of...
Articles
Advancing Automation and Digitalization in the Industrial Microbiology Workflow
Industrial microbiology is a critical function in the biopharmaceutical sector as its purpose is to monitor for contamination events and inform development of standard operating procedures to minimize the risk of contamination As the industry makes the shift to digitalized labs you will see more automation digitalization
Research Insights
Effects of COVID-19 Vaccine Safety Framing on Parental Reactions
Despite the benefits and worldwide approval use of COVID vaccination for children parents still remain a high level of vaccine hesitancy due to concerns about vaccine safety Growing evidence showing that behavioral nudges
Case Studies
Diagnostics - Stable Aqueous Horseradish Peroxidase
Challenge The main use of Horseradish peroxidise HRP is in diagnostic applications to produce a detectable signal indicating presence of a molecular target Typically HRP is used in conjugates with antibodies the antibody to recognise the molecular target an
Techno Trends
Spruce Biosciences Introduces Breakthrough TA-ERT for the Treatment of Sanfilippo Syndrome Type B
Spruce Biosciences has introduced Tralesinidase Alfa Enzyme Replacement Therapy TAERT as an investigational therapy that has received FDA Breakthrough Therapy Designation for the treatment of Sanfilippo Syndrome Type B MPS IIIB
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Nanotechnology Strategies for Age –Related Macular Degeneration
Aira Sarkar is pursuing B. Tech (Pharmaceutical Chemistry and Technology) in Department of Pharmaceutical Science and Technology, Institute of Chemical Technology (ICT).
Sathish Dyawanapelly is working as an Assistant Professor in Department of Pharmaceutical Science and Technology, Institute of Chemical Technology (ICT).
Commissioning the 505(b)(2) Pathways in Hastening the Clinical Translation of Various Drugs via Nanotechnological Approaches
Saurabh Srivastava is Associate Professor in Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. He carries more than 15 years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Wockhardt research centre and Dr. Reddy’s Laboratories for development and commercialisation of various NDA and ANDA based products for different regulated markets. He is actively involved in execution of several Industrial and Govt. aided research projects for establishment of novel differentiated (505 b 2) product development. He has 02 Commercial Products, 10 International and National Patents, 01 Edited book, 10 Book chapters along with 25 research publications in Journals of International repute to his credit.
Saurabh Shah is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Hyderabad. He has published 2 research papers, 4 review articles and 2 book chapters in renowned journals. His research focus lies in hastening the clinical translation of nanomedicine-based products from bench to bedside. He has also been involved in numerous industry research and development projects from laboratory to pilot scale up.
Neoteric Solvents: A Paradigm Shift in Pharmaceutical Industrial Processes
Abhinab Goswamiis currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. He has published 01 research paper, 02 review articles and 01 book chapter in renowned journals/international book. His research focus lies in developing the neoteric solvents-based injectable dispersions for intra-auricular administration. He has also identified few neoteric solvents potential for converting them into nanomedicines.
Datta Maroti Pawde is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. He has published 05 research papers, 05 review articles and 03 book chapters in renowned journals/international book. Using the dual drug-loaded emulsions at lab-and pilot-scale, the intraarticular injections are developed to treat inflammatory conditions produced at articular or periarticular structures.
Syed Nazrin Ruhina Rahman is currently pursuing her Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. She has published 02 research papers, 06 review articles and 04 book chapters in renowned journals/international book. Her research focus lies in managing the dry-eye syndrome by the topical application of cyclosporin A-loaded cationic emulsions.
Faculty Member, SB College of Pharmacy
Tamilvanan Shunmugaperumal is currently working at National Institute of Pharmaceutical Education and Research, Guwahati. He has published 58 research papers, 24 review articles and 08 book chapters in renowned journals international book. He is also author of 07 international books and holding 04 granted patents, 03 copyrights materials, etc.. His industrial-oriented research resulted in transfer of cationic emulsion formula from lab to industry.
USN Murty is currently working as Director of National Institute of Pharmaceutical Education and Research, Guwahati. He is the man of antimalarial research especially finding molecular leads from plant sources. He holds more than 100 research papers, few review articles and granted patents along with copyrights materials. His articulation in bioinformatics subjects is remarkable and he is the ardent user of artificial intelligence and machine learning in health-related platform.
Untapped Opportunities in Southeast Asia
Sue Lee has worked for World Courier for 25 years. During this time she has experienced a variety of customer service and operational functions, including the setting up of numerous, multi-national, clinical sites for the transportation of biological samples. She orchestrated the shipping of thousands of shipments with very specific temperature requirements to a host of challenging locations, and each presenting their own obstacles and dilemmas.
The Value in Decolonising Drug Discovery
Jesse Grey Eagle (Oglala Lakota) is the founder of Indigenous Futures OS and a governance designer for Tribal nations. He works at the nexus of ethical data, AI sovereignty, and long-view institutional systems, advocating for partnership architectures that move beyond extraction.
Sabah Ul-Hasan is a Ph.D. scientist with over 15 years of practice in the life sciences. An Indian-Pakistani American based in Albuquerque (New Mexico), Dr. Ul-Hasan centers on ethical data practices that bridge science with community-based knowledge systems.
press releasesRead more...
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
AstraZenecas ETCAMAH camizestrant in combination with a cyclindependent kinase CDK inhibitor abemaciclib palbociclib or ribociclib has been approved in the US for the treatment of adult patients
Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026
As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders
Researchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering Platform
Integrated DNA Technologies IDT a Danaher company and a global leader in genomics and Ansa Biotechnologies Inc a trusted partner for DNA synthesis today announced an expansion of their partnership
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience
Biocytogen Pharmaceuticals Beijing Co Ltd Biocytogen SSE HKEX today announced that it has entered into a nonexclusive licensing agreement with Qilu Pharmaceutical Co Ltd
Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates
Heidelberg Pharma AG FSE HPHA a clinicalstage biotech company developing innovative Antibody Drug Conjugates ADCs today announced that its whollyowned subsidiary Heidelberg Pharma Research
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Eisai Co Ltd and Biogen Inc Nasdaq BIIB announced today that the National Medical Products Administration NMPA of China has approved the subcutaneous formulation subcutaneous autoinjector SCAI
EventsRead more...
03 - 05
Sep 20265th MENA Congress for Rare Diseases 2026
Beach Rotana Hotel, Abu Dhabi,...
14 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
14 - 16
Sep 202615 - 17
Sep 2026COPD Drug Development Summit 2026
Street, Boston, MA 02210, USA
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
22 - 23
Sep 2026PDA Advanced Parenteral Therapeutics & Quality Summit
Illume Hotel Taipei, Taiwan
22 - 24
Sep 2026InsurInnovator Connect Asia
Singapore
LATEST NEWSRead more...
ZANVASTRO approved by FDA as first disease-modifying treatment for Alexander disease
Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for ZANVASTRO zilganersen to treat Alexander disease AxD in paediatric and adult patients
Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026
As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders
HUTCHMED Enters into Agreement with GSK for Novel KRAS-EGFR Cancer Therapy
HUTCHMED has entered into an exclusive development and licensing agreement with GSK for HMPLA an investigational antibodytargeted therapy conjugate ATTC designed to target KRAS and EGFR in solid tumours
Everest Medicines Receives Approval for CARDAMYST to Treat Acute PSVT
Everest Medicines has received approval from Chinas National Medical Products Administration NMPA for CARDAMYST etripamil nasal spray for the conversion of acute symptomatic episodes
HUTCHMED Announces Approval of ATLED® (Fanregratinib) for FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
HUTCHMED has received conditional approval from Chinas National Medical Products Administration NMPA for ATLED fanregratinib to treat adults with advanced metastatic or unresectable intrahepatic cholangiocarcinoma ICC with FGFR fusion or rearrangement who have previously received systemic therapy
Osivax Enters into Collaboration with GC Biopharma to Develop Next-Generation Influenza Vaccine
Osivax and GC Biopharma have entered into a strategic collaboration to develop and commercialise a nextgeneration seasonal influenza vaccine designed to provide broader and more durable protection against a range of influenza strains